氟维司群对比阿那曲唑作为绝经后女性晚期乳腺癌二线治疗的疗效 - Suppr

Suppr

超能文献

Fulvestrant versus anastrozole as second-line treatment of advanced breast cancer in postmenopausal women.

作者信息

Vergote I

机构信息

Department of Gynecologic Oncology, University Hospitals Leuven, Leuven, Belgium.

出版信息

Eur J Cancer. 2002 Nov;38 Suppl 6:S57-8. doi: 10.1016/s0959-8049(02)00287-3.

DOI:10.1016/s0959-8049(02)00287-3

PMID:12409076

Abstract

摘要

相似文献

Fulvestrant versus anastrozole as second-line treatment of advanced breast cancer in postmenopausal women.

Eur J Cancer. 2002 Nov;38 Suppl 6:S57-8. doi: 10.1016/s0959-8049(02)00287-3.

Fulvestrant 250 mg versus anastrozole 1 mg in the treatment of advanced breast cancer: a meta-analysis of randomized controlled trials.

Asian Pac J Cancer Prev. 2014;15(5):2095-100. doi: 10.7314/apjcp.2014.15.5.2095.

Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study.

Breast Cancer Res Treat. 2012 Nov;136(2):503-11. doi: 10.1007/s10549-012-2192-4. Epub 2012 Oct 13.

Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.

Cancer. 2003 Jul 15;98(2):229-38. doi: 10.1002/cncr.11468.

Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial.

Lancet Oncol. 2013 Sep;14(10):989-98. doi: 10.1016/S1470-2045(13)70322-X. Epub 2013 Jul 29.

Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study.

J Clin Oncol. 2015 Nov 10;33(32):3781-7. doi: 10.1200/JCO.2015.61.5831. Epub 2015 Sep 14.

Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.

J Clin Oncol. 2002 Aug 15;20(16):3386-95. doi: 10.1200/JCO.2002.10.058.

Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial.

Cancer Chemother Pharmacol. 2011 Jan;67(1):223-30. doi: 10.1007/s00280-010-1483-x. Epub 2010 Oct 12.

Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.

J Clin Oncol. 2002 Aug 15;20(16):3396-403. doi: 10.1200/JCO.2002.10.057.

Combination anastrozole and fulvestrant in metastatic breast cancer.

N Engl J Med. 2012 Aug 2;367(5):435-44. doi: 10.1056/NEJMoa1201622.

引用本文的文献

From Pure Antagonists to Pure Degraders of the Estrogen Receptor: Evolving Strategies for the Same Target.

ACS Omega. 2021 Mar 30;6(14):9334-9343. doi: 10.1021/acsomega.0c06362. eCollection 2021 Apr 13.

Phase II Trial of Goserelin and Exemestane Combination Therapy in Premenopausal Women With Locally Advanced or Metastatic Breast Cancer.

Medicine (Baltimore). 2015 Jul;94(26):e1006. doi: 10.1097/MD.0000000000001006.

Breast cancer management in the elderly.

Clin Transl Oncol. 2014 Apr;16(4):351-61. doi: 10.1007/s12094-013-1113-2. Epub 2013 Oct 2.

Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.

Cochrane Database Syst Rev. 2009 Oct 7;2009(4):CD003370. doi: 10.1002/14651858.CD003370.pub3.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Fulvestrant versus anastrozole as second-line treatment of advanced breast cancer in postmenopausal women.

作者信息

Vergote I

机构信息

Department of Gynecologic Oncology, University Hospitals Leuven, Leuven, Belgium.

出版信息

Eur J Cancer. 2002 Nov;38 Suppl 6:S57-8. doi: 10.1016/s0959-8049(02)00287-3.

DOI:10.1016/s0959-8049(02)00287-3

PMID:12409076

Abstract

摘要